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DOW CORNING AND THE SILICONE IMPLANT CONTROVERSY 
During 1991, the silicone breast implant issue created an 
unprecedented challenge for Dow Corning that will continue for 
some time. We are taking responsible action to resolve the situation 
in the best interests of the needs and concerns of women. 1 ask that 
you keep infonned so that you can represent your company 
accurately to customers, suppliers and members of our communities. 
And 1 encourage you to keep the issue in perspective and not allow 
the extensive media coverage to distract you from the fulfillment of 
your jobs. 
lAwrence Reed 
President & COO 
Dow Corning Corporation 
1991 Report for Employees 
The silicone breast implant fiasco is a sad case of corporate 
indifference and regulatory mismanagement. 
Representati~·e Ted Weiss (D-N. Y.) 
House Subcommittee Chainnan 
New York Times, 3120192 
On April 16, 1992, the US Food and Drug Administration (FDA) lifted its 
January 6 moratorium on silicone gel-filed breast implants, but limiting availability and 
use for only special conditions. Given its concern about implant safety, the FDA 
required all future recipients to enroll in clinical studies. In its May 27, 1992 Update 
On Silicone Gel-Filled Breast Implanrs, the FDA acknowledged that "there is public 
health need for the implants among patients who have lost a breast because of cancer 
or trauma, or who have a serious malformation of the breast requiring reconstruction. 
Thus any woman who needs the implant to reconstruct the breast will be permitted 
access to such studies. Implants for the purpose of augmentation (breast 
enlargement) will be available only to a very limited number of women who 
This case is intended as a basis for class discussion rather than to illustrate either 
effective or ineffective management. No judgment or conclusion is implied either for 
or against any individual , organization or institution. Every attempt has been made to 
report information accurately and all information sources are cited where appropriate. 
Copyright (c) 1992 Zarina S. F. Lam and Dileep Hurry. 
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are enrolled in controlled clinical studies approved by FDA and designed to study 
specific safety questions relevant to the device." 
THE IMPLANT MARKET AND INDUSTRY PRIOR TO APRIL 1992 
The breast implant market generated annual revenues of approximately $500 
million prior to the controversy. The FDA estimates that approximately 2 million 
women in the U.S. have received breast implants. 1 Since their introduction in 1964 by 
Dow Corning, silicone-filled breast implants gained popularity2 and had slowly shifted 
from being predominantly reconstructive to being used for cosmetic augmentation 
purposes. The FDA estimated that 80% of the procedures were performed for 
cosmetic reasons and 20% for reconstructive purposes (for cancer patients who had 
undergone mastectomies). According to Business Week (6110/91), breast implants 
formed the third most popular procedure in plastic surgery after nose reconstruction 
and liposuction. Between 100,000 and 150,000 implant procedures were performed 
each year until the FDA's moratorium in January 1992. According to the Los Angeles 
Times (117/92), surgeons' fees accounted for the bulk of the implant industry's $500 
million revenues in 1991. Sales of the devices totaled about $50 million in 1991. 
The industry consisted of the following firms prior to April 1992: 
Dow Corning Corporation 
Dow Corning Corporation was the world's first and largest silicone gel-filled 
breast implant manufacturer. It commanded approximately 35% of the market3 until 
March 19, 1992 when the company withdrew from the market. Founded in 1943, Dow 
Corning is a 50/50 joint venture of Dow Chemical Company and Corning 
lTwo estimates made by the FDA stated that some I million women have breast implants in place. All 
other references gave the 2 million women estimate. 
2Between 1981 and 1988, the number of procedures done nationally grew 63% to 620,000. 20% of the 
operations performed annually in the U.S. were done in New York, second only to Los Angeles. (New 
York Business Journal, 1113/92). 
3The American Medical News states that Dow Coming had a 20% share of the breast implant market. 
Other references ret1ect the 35% market share. According to Canon Communications, Inc., publisher of 
the Medical Device and Diagnostic Industry, there is no official market share information. There is no 
dispute, however, of Dow Coming's market leader status. 
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Incorporated. Its principal business is to develop, manufacture and market silicones, 
related specialty chemicals, polycrystalline silicone, and specialty health care products. 
Operating worldwide, Dow Coming is a diversified, high technology firm with around 
5,000 products, 40,000 customers, 8,000 employees, and 4,900 total active worldwide 
patents (1,300 U.S. active). In 1991, 8% of its sales revenue was spent on research 
and development. Three related companies are Hemlock Semiconductor Corp., which 
manufactures polycrystalline silicon, Dow Coming STI which makes silicone rubber, 
and Dow Coming Wright, a manufacturer of orthopaedic medical devices. Dow 
Corning Wright was the division responsible for silicone implants. 
Company estimates suggest that there were approximately 750,000 Dow 
Corning implants worldwide by 1991. ~ccording to the company's 1991 Repon for 
Employees, despite an 8. 1 % increase in sales revenue in 1991 ($1, 845 million ending 
12/91), net income ($153 million) fell 10.6% from 1990. Dow Corning explained, 
"Profits were hurt by charges for anticipated venture losses, legal contract disputes, and 
breast implant matters. These charges reduced 1991 Profit After Tax by $36 
million. "4 Implant sales, however, generated less than 1% of Dow Corning's 1991 
sales revenues.5 See Exhibit 1 - Company Financial History. 
Dow Coming first entered the silicone-filled breast implant market in 1964 
when the Cronin Implant was invented by Senior Surgeon Tom Cronin at Dow 
Corning. Market resistance to the thick gel and shell led to a modified design in 1969, 
which included a seamless envelope and softer silicone gel. However, according to 
4Dow Corning stopped producing silicone-gel tilled breast implants and took a $25 million charge 
against 4th quarter 1991 earnings, which included a $10 million research fund announced on 3/19/92. 
(Wall Street Journal , 1/15/92). 
5According to attorney Daniel Bolton, Dow Coming was responsible for the original national testing of 
silicone breast implants, a position which later subjected the company to being named as CO-defendants 
in lawsuits against other implant makers. 
4 
Tom Talcott, an employee at Dow Corning between 1952 to 19766, the modified 
design had a higher failure rate than the earlier design. 
Subsequent product redesign led to the SILASTIC MSI Brand Mammary 
Implant H.P. Gel Filled design. The SILASTIC MSI Mammary Implant H.P. is a 
silicone gel-filled breast implant made with a micro structure silicone envelope. The 
silicone envelope consists of medical grade high performance (H.P.) silicone elastomer 
with an integral surface micro structure and a fluorosilicone barrier layer laminated to 
the inner surface of the envelope. The company's product information stated that the 
fluorosilicone coating within the envelope provided an effective barrier to significantly 
reduce "gel bleed", the passage of small quantities of silicone through the elastomeric 
shell of the implant. (If the gel happened to become mixed with body fluids, it may 
lose viscosity, and hence possibly be more difficult to remove). The company 
maintained that the product was safe and that most women were, and would continue to 
be, happy with their implants (New York Times, 3/20/1992). 
In its 1992-93 Profile, the company detailed eight basic corporate values: 
Integrity, Employees, Customers, Quality, Technology, Environment, Safety, and 
Profit. See Exhibit 2 - Dow Corning Corporate Values. These values were also 
retlected throughout its 1991 Reporrfor Employees. 
Other Implant Makers 
In addition to Dow Corning, there were several silicone breast implant makers 
m early 1992, including Surgitek, a subsidiary of Bristol-Myers Squibb, McGhan 
Medical Corp., a subsidiary of !NAMED Corporation of Carpinteria, CA, Mentor 
Corporation of Santa Barbara, CA, and Bioplasty of Roseville, MN. 
6In fall 1974, Talcott was made a member of the task force for the biological testing of the second 
generation breast implants. Talcott contends that the silicone gel breast implant was too fluid, posing a 
potential danger to the patient and presented his recommendation to suspend the product to the group in 
1975. Following unsuccessful pleas, Talcott resigned in protest in 2176. Information provided by 
Talcott was a factor in the FDA's decision to impose the moratorium on l/6/92. 
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Bristol-Myers Squibb 
Headquartered in New York, NY, Bristol-Myers Squibb manufactures and 
distributes cardiovascular and other pharmaceutical products, medical devices such as 
orthopaedic implants and surgical instruments, non-prescription health products such as 
baby formula, toiletries, beauty aids and household products. Surgitek was the 
subsidiary responsible for the manufacturing of silicone gel implants. Preliminary data 
in a 1991 FDA study on polyurethane foam, a material used as a coating for certain 
kinds of silicone gel-filled breast implants, suggested that the foam might degrade into 
a substance called 2-toluene diamine (TDA), which has been shown to cause cancer in 
laboratory animals. 
In April 1991, Surgitek voluntarily suspended shipment of its Meme and 
Replicon polyurethane foal-coated implants and requested doctors to delay implantation 
while the FDA evaluated laboratory and risk assessment data on a possible link between 
polyurethane foam and cancer. Surgitek set up a toll free number for inquiries by 
patients and physicians. In August 1991, with litigation pending against the company, 
Bristol-Myers Squibb officially withdrew from the implant market. 
McGhan (!NAMED) Corporation 
McGhan Medical Corporation, a wholly-owned subsidiary of !NAMED, is 
engaged in the development, manufacture and sales of a number of implantable 
products, including mammary prostheses, tissue expanders and facial implants for 
plastic and reconstructive surgery as well as custom prostheses for a variety of surgical 
applications and procedures. In its mammary prosthesis product line-up for 1991, 
·McGhan produced different models, shapes and sizes of implants including but not 
limited to double-lumen, saline, and gel-filled mammary implants. The company's 
BiocellTM implant incorporates its own patented low-bleed technology along with its 
patented textured surface technology. Along with other subsidiaries of !NAMED, 
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McGhan also manufactures saline-filled mammary prostheses. A news release (January 
7, 1992) stated that the company's strategic plan for 1992 would "emphasize the 
marketing and sale of saline-filled implants to achieve a leading world-wide market 
share." Anticipating an increase in demand for saline implants (which remained 
unaffected by the FDA's moratorium), the company stepped up manufacturing levels 
and product inventories during the second half of 1991. The company has filed for 
FDA permission to continue implant operations. 
McGhan reported a net loss of $2.8 million or $.35 per share on sales of $42 
million for the year ended December 31, 1991. The company attributed the loss to the 
write-off of approximately $4.4 million of inventories and intangible assets related to 
the silicone gel-filled implants covered py the FDA regulation. The company has 
disclosed that several !NAMED subsidiaries were defendants in 130 pending court 
actions for general and/or punitive damages. McGhan is self-insured, with no product 
liability coverage on the majority of its implant products. 
Mentor Corporation 
In operation since 1969, Mentor Corporation develops, manufactures and 
markets specialized medical products in the areas of plastic and reconstructive surgery, 
urology and ophthalmology. Plastic surgery products include surgically implantable 
prostheses for cosmetic and reconstructive surgery, principally breast implants and 
tissue expanders. Urologic products include disposable products for the management 
of certain urinary/gastrointestinal disorders. Ophthalmic products include surgical 
equipment, primarily coagulators used to control bleeding during ophthalmic or other 
microsurgery, and diagnostic equipment. Headquartered in Santa Barbara, CA, Mentor 
has manufacturing and research facilities in California, Massachusetts, Minnesota, 
Missouri and Texas. According to company records, Mentor's plastic surgery business 
accounts for about 30% of revenues. Mentor produces both silicone-gel implants and 
saline-filled implants used for breast augmentation and reconstruction in connection 
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with congenital deformity or following cancer surgery, or for other medical reasons. 
Mentor's 1992 Annual Report states, "we purchased the silicone gel used in our 
implants from an outside supplier and believe that it is the responsibility of that supplier 
to defend it and indemnify us against claims of injurious effects on the body. '17 Mentor 
is filing for premarket approval and is resuming shipment of silicone gel implants in 
accordance with the FDA guidelines. 
Bioplasty, Inc. 
Headquartered in Roseville, MN, Bioplasty manufactures and markets medical 
products. In an interview with the Minneapolis-St. Paul City Business Journal in 
January 1992, Bioplasty CEO Arthur Beisang said that the company awaited FDA 
approval to start selling its non-silicone implants. The company withdrew its MIST! 
GOLD implant PMA application in 1991 after the FDA said that the company did not 
have enough data to prove the product's safety. According to Beisang, Bioplasty' s 
other implants are made of an inorganic polymer that, unlike silicone, is excreted by 
the body if the implant ruptures. Following the FDA's moratorium and its panel 
recommendation to restrict the use of silicone gel-filled implants in early 1992, 
Bioplasty withdrew from the market. 
THE SILICONE IMPLANT CONTROVERSY 
In the 1980s, silicone implants came under scrutiny for possible implant rupture 
and migration of silicone into the recipient's body, allegedly resulting in mixed 
connective tissue disorders. However, there were apparently two sides to this issue, as 
detailed below: 
7The silicone gel used in Mentor' s implants was supplied by Dow Coming. 
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Proponents for Implant Use 
Many groups supported the use of silicone implants, including implant 
recipients themselves, plastic surgeons and consumer advocacy groups. During the 
FDA hearings in late 1991, hundreds of women with breast implants testified before 
Congress about their emotional benefits. During a January 1992 news conference at 
which officials of the American Cancer Society's Texas Division reiterated their 
opposition to a ban on silicone implants, Silvia Mercado of Fort Worth, a cancer 
survivor, said, "It helped me put the episode of cancer behind me and helped me get on 
with my life." Mercado is a member of an organization called Women for Implants in 
Dallas. Similarly, Garry Brody, a member of the American Society of Plastic and 
Reconstructive Surgeons' Devices Reviewing Committee, stated in an interview with 
USA Today (January 21, 1992) that "problems surrounding silicone implants are rare 
and uncommon." 
While silicone-lined saline-filled implants provide an alternative, they are not 
recommended in certain mastectomy cases and are more likely to puncture or shift, 
according to Dr. George Peters, President of the Texas Division of the American 
Cancer Society's Texas Chapter and a breast cancer surgeon at Baylor University 
Medical Center (Dallas Morning News, 1/92). Experts appear to agree that the 
consistency of the silicone gel most resembles that of the human tissue. It is also easy 
to work with as far as molding and forming, says Jerry Kuester, who researches 
medical device safety concerns for the Public Citizen Health Research Group (USA 
Today 1/ 21/92). 
Opponents to the Implants 
Opponents of the silicone breast implant contend that Dow Corning and other 
implant makers withheld information regarding the silicone implants and failed to 
9 
inform the implant recipients of potential danger. 8 Among the critics is Tom Talcott, 
a former member of Dow Corning's product development task force from 1974 to 
1976. Mr. Talcott has stated that his efforts to express concern over the silicone gel 
breast implant to members of the product and marketing team at Dow Corning were 
unsuccessful. According to information provided by Talcott, he contended that while 
Dow Corning's management agreed that the gel should not be placed directly in human 
breasts, they believed that it would be acceptable to store the fluid in a biological 
capsule or envelope. Talcott's belief has spurred him to lead a crusade in breast 
implant litigation over the past 10 years. 
DOW CORNING: LITIGATION AND RESPONSES 
Dow Corning's silicone gel-filled breast implants first came under legal scrutiny 
in 1984 when a San Francisco federal court jury concluded that the company had 
committed fraud in marketing its implant as safe. The jurors awarded Maria Stern of 
Nevada $1.5 million in punitive damages. Dow Corning appealed and the case was 
settled for an undisclosed sum. (Business Week 6110/91). Following the Stern case, 
Dow Corning changed its product literature to include a warning intended for surgeons 
to pass along to patients. A 1985 package insert mentions the possibility of immune 
system sensitivity and possible silicone migration following rupture. A 1987 company 
"position statement" discounted the immune-system problem, saying it was linked to 
silicone of lesser purity than was used in the company's implants. Shortly after, the 
company began a program to replace ruptured implants and those removed because 
patients complained of adverse reactions.9 
8The National Resources Defense Council and Consumers Union approached Dow Coming, Bioplasty, 
McGhan Medical and Mentor with the information that their top officials could be jailed if they do not 
comply with California's corporate criminal liability law and disclose all product hazards. (Wall Street 
Journal 1117 /92) 
9Jn the Supplemema/ Information to Most Frequem Questions prepared by the Dow Corning Information 
Center, the company states, '"The number of cases of connective tissue disease reported in women with 
silicone breast implants is small and likely within the number expected by chance alone ... The first cases 
of possible connective tissue disease were published in Japan in 1964. Over the past 26 years, more than 
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In 1988, Mariann Hopkins sued Dow Corning with attorney Daniel Bolton who 
had represented other implant recipients. Hopkins refused several Dow Corning 
attempts to settle out of court, the last of which amounted to $1.8 million. (Dallas 
Morning News, 2/92). The New York Times reported on December 17, 1991, the 
jury found Dow Corning guilty of fraud and malice in marketing the implants and 
awarded Hopkins $7.3 million, the largest amount ever in an implant suit.lO The 
lawsuit contended that the disease was caused by a leak of the gel. Hopkins received 
the silicone implants in 1976 following a double mastectomy. Hopkins was diagnosed 
with mixed connective tissue disease, an irreversible, autoimmune illness with 
symptoms similar to those of rheumatoid arthritis. In response to the verdict, Dow 
Corning published the following statement, "We are particularly disappointed because 
·, 
the jury still make this unjustified award to the plaintiff, despite the fact that two of her 
doctors - whom Dow Corning called as witnesses - said in court that the plaintiff's 
mixed connective tissue disease preceded her breast implant surgery." Dow Corning 
charged that symptoms of the plaintiff's mixed connective tissue disease were identified 
at least two years before she had the breast implants. According to Bolton, there are 
approximately 200 law suits pending against Dow Corning. Other implant makers are 
also being sued for damages. It has been reported that Dow Corning's breast implant 
legal liability could exceed $1 billion.ll 
The company's overall position on the role of its implants can be summarized in 
the words of Mr. Robert Rylee, Chairman Healthcare Businesses, Dow Corning 
Wright, "It is not my role in life, nor our company's role, to tell her (potential implant 
100 cases have been publishcd in the medical literature on women who have developed connective tissue 
disease. l /3 of these women have silicone breast implant devices. " 
lOThe company is appealing the decision. 
liThe liability does not stop at Dow Coming. Dow Chemicals and Coming, the parent companies, have 
been sued by an investor, who accused the tirms ' joint venture of securities law violations and of 
allegedly not revealing possible problems concerning the firm's silicone gel breast implants. (Wall Street 
Journal, 1/20/92). CNN's MoneyLine 4/13/92 broadcast stated that potential law suits against all breast 
implant makers may potentially exceed $1 - 2 billion. 
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recipient) that she cannot do that. I think it is important for the woman to have the 
right to make that choice, to make an intelligent, informed decision." (Wall Street 
Journal 1114/92). 
THE FDA'S ROLE- THE MEDICAL DEVICE AMENDMENTS OF 1976 
Silicone breast implants had been available in the US. for more than 30 years 
prior to the moratorium. The first implant was reported to be available on the market in 
1962 when the FDA did not have jurisdiction over device regulation. On May 28, 
1976, the Medical Device Amendments to the Food, Drug and Cosmetic Act of 1938 
went into effect, empowering the FDA to regulate medical devices through the 
establishment of a premarket approval process similar to that for drugs. However, the 
FDA had neither the resources nor the inclination to launch countless new 
investigations.12 Consequently, about 90% of the devices already on the market, 
including silicone breast implants, were "grand fathered" out of the approval process. 
(American Medical News 2117/92). Under the Medical Device Amendments, devices 
are categorized into three classes: 
Class I devices: Those devices for which "general controls are sufficient to provide 
reasonable assurance of the safety and effectiveness of the device" (e.g. adhesive 
bandages, toothbrushes, eyeglasses, and thermometers). 
Class II devices: Those devices for which "a performance standard exists to provide 
reasonable assurance of safety and effectiveness" (e.g. cardiac monitors, anesthesia 
machines and defibrillators, and magnetic resonance imagers). 
Class III devices: Those devices "purported or represented to be for a use in 
supporting or sustaining human life or for a use which is of substantial importance in 
preventing impairment of human health, or presents a potential unreasonable risk of 
illness or injury" e.g. silicone-gel breast prostheses (implants), IUDs, endolymphatic 
shunts, and osseous implants. In 1986, approximately 140 devices, or 8% of the total, 
were in Class III. 
12According to the May 1986 issue of FDA Consumer, the number of premarket approval applications 
increased by about 56% from 1980 to 1985. With the rising workload and the greater complexity of 
devices, the amount of review time increased from an average of 230 days per application in 1980 to 
about 350 days in 1985. The Center for Devices and Radiological Health had streamlined the internal 
review procedures and issued guidelines for manufacturers. 
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Following these amendments, manufacturers of Class III devices were required 
to do one of two things: either submit evidence for reclassification as Class I or II 
device, or file a premarket approval (PMA) application, accompanied by scientific data 
sufficient to establish the product's safety and efficacy. In June 1988, the FDA 
classified the implants into Class III - which gave it the authority to ask for safety and 
effectiveness data after the prescribed waiting period of 30 months. 
With the prioritizing of devices to receive PMA approval notification, breast 
implant manufacturers were not officially notified until May 17, 1990, when a notice 
appeared in the Federal Register proposing a regulation to require silicone breast 
implant manufacturers to file PMAs. On April 10, 1991, the FDA issued a final ruling 
requiring all manufacturers of silicone gel-filled mammary prostheses to file premarket 
approval applications for each specific mammary prosthesis they intend to market with 
the FDA within 90 days after the effective date of the regulation, or cease sale and/or 
distribution of their products. See Exhibit 3 - Silicone Breast Implant Health Risks. 
With this ruling, implant manufacturers had until July 9, 1991, to file premarket 
approval applications. By July 9, 1991, several implant makers, Dow Corning Wright, 
McGhan Medical Corporation, Mentor Corporation, Bioplasty, Inc., and Surgitek 
(Bristol-Myers Squibb) submitted their safety data to the FDA for review. On August 
22, the FDA decided not to proceed with a full-scale review of the safety and 
effectiveness data submitted by three manufacturers of silicone gel-filled breast 
implants "because the submissions contain little or no information based on human 
studies." Affected were applications submitted by Joseph F. Cavon, MD, of Santa 
Ana, CA., Surgitek, and Bioplasty for its MIST! GOLD model. Applications by Dow 
Corning, McGhan, Mentor, and Bioplasty for its other models would undergo the full 
review process. According to Dow Corning's records, the company submitted 50,000 
pages of information addressing 30 years of safety studies, manufacturing processes, 
product design and labeling on July 8, 1991. 
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On November 15, following testimony by FDA scientists and implant 
manufacturers, the FDA's General and Plastic Surgery Devices Panel advised the FDA 
that data submitted by the four manufacturers of silicone gel-filled breast implants did 
not provide reasonable assurance of the safety and effectiveness of these devices. 
However, the panel chairperson, Dr. Elizabeth Connell of Emory University School of 
Medicine, emphasized that the group did not find evidence that the implants were 
unsafe and that there was not enough information about the risks and benefits of their 
use. Despite the lack of data, the panel of outside experts voted unanimously to advise 
the agency that the implants serve a public health need and that they should continue to 
be available while the manufacturers collect additional data. Under the law, the agency 
had 180 days from the day of the commi~tee' s non-binding recommendations to decide 
whether to approve silicone gel-filled breast implants for continued marketing. 
The Voluntary Moratorium 
A number of hearings were held during the months of November and 
December. On January 6, 1992, FDA Commissioner Dr. David Kessler called for a 
voluntary moratorium on the use of silicone gel-filled breast implants until "new 
information" on their safety could be thorough! y reviewed by an independent advisory 
panel and the agency could make a final decision in light of the panel's review. In 
addressing the press, Dr. David Kessler said, "Women considering breast implants 
deserve to know whether these products are safe enough for use. I'm calling for a 
delay in the use of these products until our advisory panel can meet to consider new 
information which was not available when it met in November." Part of the "new 
information" included some 90 Dow Corning documents comprising 10 scientific 
reports or studies and 80 memos and company documents. These documents were 
revealed during a product liability case against Dow Corning Wright.13 
13The Wall Street Journal (1113/92) reported the following: "There is evidence that the firm (Dow 
Coming) rushed a silicone-gel implant to market in 1975 after a crash development program undertaken 
to insure that the product would be made available in time to be grandfathered out of device legislation." 
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The FDA's concerns about the implants were stated by Dr. Kessler as follows: 
We still do not know how often the implants leak, and when they do, we do not 
know exactly what materials get into the body. 
We still do not know how often the implants break, or how long they last. 
We still do not know how often women with the implants suffer adverse effects. 
For example, there are reports that painful hardening of the implant can occur in 
anywhere from 10% to 70% of patients. 
We still do not know to what extent the implants interfere with mammography 
examinations. This is especially important because the implants have been used in 
thousands of healthy women each year. 
We still do not know whether the implants can increase a woman's risk of 
developing cancer. 
And we still do not know enough about the relationship between these devices and 
autoimmune and connective tissue diseases. 
Per the moratorium, manufactu~ers were requested to stop distributing the 
devices and plastic surgeons were requested to stop recommending them until the 
agency could review further data on the safety of silicone implants. Unless a woman is 
having problems with her implants, the FDA does not recommend that the implants be 
removed. However, if a woman is having symptoms suspected of being implant 
related, she should seek a doctor's advice. 
The Panel 1s Final Recommendations 
In its Advisory Panel Meeting on February 18 - 20, the panel recommended 
that FDA permit the use of the implants under clinical protocols that will allow access 
to all women requiring breast reconstruction. (Medical Devices Bulletin 2192) 
However, the panel reached a consensus that there was insufficient data to show a cause 
and effect relationship between implants and certain immune-related or connective 
tissue disorders. 
Talcott's testimony and internal memos pointed to the hasty development program. According to 
company documents and as Talcott contends, Dow Corning had thought that silicone might spur some 
immune response. Although the implants were tested on animals, there is no evidence that the devices 
were tested in or under animal breast tissue (New York Times, l/13/92). 
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The FDA Decision 
The panel's recommendations were incorporated into the FDA's decision on 
April 16, 1992, when the FDA lifted the moratorium. Silicone-filled breast implants 
are now restricted to patients with breast cancer, traumatic injuries and serious 
congenital deformities, and women participating in clinical studies. The moratorium 
was lifted in three stages: Stage 1 began on April 20, 1992, for women whose breast 
reconstruction began before the moratorium with placement of a temporary tissue 
expander and who were awaiting a permanent implant and women whose implants have 
ruptured. Stage 2 would take several months to set up and will consist of clinical 
studies open to breast cancer patients and women with serious breast injuries and 
abnormality. Stage 3 includes intensive research studies and prospective clinical 
investigations open to limited number of women for reconstructive or cosmetic 
purposes. With the decision, the FDA is working with manufacturers to set up a 
centralized registry so that women with implants can be notified quickly of significant 
new findings about the devices. The FDA also requires further laboratory studies to 
look at the chemical composition and toxicity of the silicone material that "bleeds" out 
of the implant shell, the strength of the implant shell, its resistance to rupture, and the 
physical and chemical changes that the implants may undergo in the human body . 14 
DOW CORNING'S FINAL DECISION 
Dow Corning's response to the controversy took shape through several 
measures: In early 1991, the company set a $250 million insurance fund to cover its 
potential implant liability. On July 24, 1991, it opened the Implant Information Center 
to provide facts about silicone breast implants to women through a toll free number. 
On January 29, 1992, the company retained a special counsel to conduct a complete 
14Further information may be obtained from the FDA by calling 1-800-532-4440 or 1-800-688-6167 for 
the hearing impaired. 
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investigation of its development, production, and marketing of silicone breast implants. 
The investigation will also examine the appropriateness and timeliness of management 
judgments and decisions over the development of the product. Dow Corning said that 
it has taken this action to provide an independent objective forum for a reasoned review 
by qualified experts regarding its conduct in the development and marketing of this 
device. At the conclusion of the investigation, a written report will be made available 
to the FDA and the general public. 
To cooperate with the FDA, Dow Corning released 15 reports of scientific 
studies and 94 internal, non-scientific company documents on February 10, 1992, 
following allegations of withholding relevant data. At the same time, it appointed 
Keith R. McKennon, formerly Execut.ive Vice President of The Dow Chemical 
Company, as Chairman of the Board and CEO of Dow Corning, replacing Lawrence 
Reed who will continue as President and COO. As CEO, McKennon would focus on 
the complex issues related to silicone breast implants, while Reed would direct Dow 
Corning's global operations, the company said. 
Finally, on March 19, 1992, McKennon ended the company's 30-year trade in 
silicone gel implants worldwide and announced a $10 million research fund to continue 
the study of silicone breast implant safety. "The single, most important objective of 
this research is to answer those remaining questions women may have about their 
implants," said McKennon. Dow Corning also reaffirmed its program to provide 
financial support for implant removals.15 Dow Corning withdrew its Pre-market 
Approval Applications on April 14, 1992. 
THE INDUSTRY AFfER APRIL 1992 
By summer 1992, there are only two manufacturers still actively pursuing the 
implant market: McGhan Medical Corporation and Mentor Corporation, both of 
15This program provides up to $1,200 of medical assistance per patient. The cost of implant removal is 
estimated from $500 to $5,000, depending on situation. 
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California. In a news release (May 18, 1992), McGhan Chairman of the Board Donald 
K. McGhan said, "Although the Company is still unable to manufacture or ship gel-
filled implants, our customers are accepting the Company's saline-filled implants for 
most applications. The Company does expect to renew manufacturing and shipping of 
gel-filled implants as soon as the FDA allows." Meanwhile, Mentor, saw Dow 
Corning's and other manufacturers' withdrawal a welcomed opportunity. In its 1992 
Annual Report (year ended 3/31/92), the company states, "We are looking forward to 
serve the needs of the market while working with the medical profession and the FDA 
to increase our knowledge and advance the technology of breast implants." Mentor 
reported record sales and earnings for the first quarter ended June 30, 1992. According 
to the company's news release dated 711.6/92, "Sales growth was led primarily by a 
resurgence in plastic surgery sales following the lifting of the FDA moratorium on 
breast implants, by strong international sales, and by a strong performance from 
urological surgical products." 
The recommendation reflected the panel's struggle to balance the 
obligation to ensure that devices are safe and effective with the 
effort to meet a compelling public health need. 
American Medical News, March 9, 1992 
Let me make very clear that Dow Corning remains satisfied that 
Dow Corning implants produced over the years have filled an 
important medical need for thousands of women, and did not and do 
not represent an unreasonable risk. Based on past experience, we 
believe that the vast majority of women who have our implants will 
remain satisfied with the device. Our reasons for not resuming 
production and sales, therefore, are not related to issues of science 
or safety but to the existing condition of the marketplace. 
Keith McKennon, Chainnan of the Board & CEO 
Dow Corning Corporate News, March 19, 1992 
Exhibit 1 
Company Financial History 
Source: Dow Corning Corporation 1991 Reports for Employees 
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Dow Corning Corporate Values 
Source: Dow Corning Corporation 1992-1993 Pronie 
Integrity: 
Our integrity is demonstrated in our ethical conduct and in our respect for 
the values cherished by the society of which we are a part. 
Employees 
Our employees are the source from which our ideas, actions and 
performance flow. The full potential of our people is best realized in an 
environment that breeds fairness, self-fulfillment, teamwork and 
dedication to excellence. 
Customers 
Our relationship with each customer is entered in the spirit of a long-term 





fulfill those needs. 
Technology 
quest for quality performance is based on our 
customers' needs for our willingness and capacity to 
Our advancement of chemistry and related sciences in our chosen fields is 
the Value that more differentiates Dow Corning. 
Environment 
Our commitment to the safekeeping of the physical environment IS 
founded on our appreciation of it as the basis for the existence of life. 
Safety 
Our attention to safety is based on our full-time commitment to injury-free 
work, individual self-worth and a consideration for the well-being of 
others. 
Profit 
Our long-term profit growth is essential to our long-term existence. How 
our profits are derived, and the purposes for which they are used, are 
influenced by our Values and our shareholders. 
Exhibit 3 
Silicone Gel-Filled Implants Health Risks 
Source: FDA Federal Register, September 26, 1991 
FDA Recommended 
Patient Risk Information* 
SILICONE GEL-Fll.LED BREAST IMPLANTS 
The Food and Drug Administration believes 
that a patient considering silicone gel-filled 
breast Implants should recei,·e the following 
information about the possible risks involved. 
The patient should receive the information 
before surgef\· is scheduled. so that she has 
time to revie\\· the material and discuss it with 
her doctor. Each woman. \\'ith her doctors 
heip. must decide \\·hether she IS \\·illing to 
~tccept the nsks in order to achie,·e the 
expected benefits. \\·hich mav vary. 
depending on the condition for \\·hich the 
implant is used. 
In addition to posing the gener:.ll risks 
associated with am· surgical procedure 
(infection. delayed wound healing. etc. J. 
s ilicone gel-filled breast implants have certain 
specific risks. including: 
• Capsular contracture. The scar tissue that 
norm::lih· forms :.uound the implant can 
tighten and squeeze the implant. This 
l'Jn cause unnatural firmness. pam :.1nd. 
in se,·ere cases. a misshapen 
appe:.trance. 
• Calcium deposits in the tissue around the 
implant. This too can cmse hardening 
and pain. 
• Rupture of the implant. The implant can 
break due to injury or normal \\·ear over 
time. rele:1sing the silicone gel filling. 
• Ch:1nges in nipple ~md breast sensation. 
There c:1n be increased o r decreased 
sensation. \Yhich can be temporaf\' or 
permanent. 
• Interference with mammography. The 
implant can interfere \\'ith the detection 
of early bre:1st cancer through 
mammography because it em "hide .. 
suspicious lesions in the breast. This 
makes it difficult to perform 
mammography and to interpret the 
results. 
.-\!though thev ma\· occur m onh· ~~ :->mall 
percentage of patients. some ot these adverse 
effects. such as capsular contracture. calcium 
deposits and rupture. can require removing 
the implants. 
In addition to these kno\\·n risks. there are 
unanswered questions about silicone gel-
filled breast implants. For example. even if 
the implant does not rupture . tim· amounts o f 
the gel filling can gradual!\· escape from the 
implant and may migrate to other p:ms of the 
hodv. It is unkno\\·n \\·hether this is h:1rmful 
to health in the long run. Questions ha, ·e 
been raised abo ut \\·hether me escaoed gel 
might cause autoimmune diseases suci1 :.ts 
lupus. scleroderma and rheumato id arthritis in 
some women. o r whether it nw~ht mcre:1se 
the risk of cancer. There is no scientific 
evidence at present that \\'Omen \\'Ith breast 
implants have :1n increased risk of these 
diseases. but the possibilit\· cannot he ruled 
o ut. FDA has required the manufacturers of 
silicone gel-filled breast implants to submit 
d:J.ta to answer these questions. lIn contrast to 
the silicone gel-filled bre:.1st imp!Jnts. saiine-
filled implants conuin onlv s:.1lt ,,·ater. so am· 
risk th:lt might be related to the gel \\·ould 
not occur \\·irh these products. But since hoth 
types of impl:mts h:1\·e :1 silicone rubber 
envelope. an increased risk of JUtOimmune 
dise:.1ses o r cancer is possihle e \·en tor the 
saline-filled implants.) 
( .. "'")_ DEPARTMENT Of HEALTH & HUMAN SERVICES ·-.:~~ 
BACKGROUND INFORMATION ON 
Pubhc Health Serv1ce 
Fooa and Drug Admmistratior 
Rockviile MD 20857 
THE POSSIBLE HEALTH RISKS OF SILICONE BREAST IMPLANTS 
(PREPARED DECEMBER 18, 1990) 
(REVISED FEBRUARY 8, 1991) 
Silicone gel-filled breast implants have been used for 
approximately 20 years, and at present about 2 million women in 
the U.S. have them. When the medical device law--the statute 
that gives the Food and Drug Administration (FDA) the authority 
to regulate products such as implants--was passed in 1976, it 
"grandfathered" devices that were already on the market, 
including breast implants. This means that the manufacturers of 
those products were not required to provide FDA with scientific 
evidence of safety and effectiveness, as they are with brand-new 
types of devices. That stipulation in the law is based on the 
premise that, generally speaking, more is known about the safety 
of a device that has been in use for some time than about one 
that is newly developed. But if questions arise over time that 
cast any doubt about a "grandfathered" device's safety, the law 
also gives FDA the authority to go back and require that its 
manufacturer provide us with evidence to demonstrate that it is 
safe and effective. 
That is what FDA has chosen to do with silicone breas~ implants. 
Although it appears that most women with these implants do not 
suffer serious adverse effects, there are enough unanswered 
questions about possible risks that FDA has decided to require 
manufacturers to provide scientific data demonstrating their 
safety. 
The possible risks of silicone breast implants fall into two 
basic categories: those related directly to the breast, and those 
that may involve distant parts of the body. One breast-related 
risk is that the implant may make it more difficult to see 
abnormalities in the breast when mammographic x-ray examinations 
are done, even if special views are made as part of the x-ray 
procedure. Another is the hardening, discomfort and pain that 
occurs in some patients, resulting from fibrous tissue growing 
around the implant. Still another is occasional breakage of the 
implant's outer envelope, causing the gel filling to be released. 
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Most of these breast-related effects are relatively easy to 
observe, and they are not unexpected. All implanted devices, 
from artificial hip joints to heart valves, will fail to work or 
will have adverse effects in a small proportion of patients--no 
type of device placed in the body for a long period of time can 
be considered perfect, and no surgical procedure is without risk. 
With breast implants, FDA needs more information on what 
percentage of patients experience these breast-related effects 
and how severe they are. 
The possible effects of silicone breast implants on other parts 
of the body are far more uncertain and difficult to measure. For 
example, it is known that even in the absence of obvious leaks, 
minute quantities of the gel filling can migrate out of an intact 
breast implant over a long period of time and can travel 
throughout the body. It is not known whether this can be harmful 
over the long run or not. It has been suggested that these tiny 
amounts of silicone in the body could lead some people to develop 
auto-immune diseases in later years, and some scientists have 
raised the question of whether the silicone could have an effect 
on a developing fetus. But at this point there is no convincing 
evidence that these effects actually occur. 
The long-term effect of greatest concern to most people is the 
possibility of cancer. That concern was aroused several years 
ago by a study of laboratory rats conducted by the Dow Corning 
Corporation, a leading manufacturer of silicone breast implants. 
The study showed an excess of a particular type of cancer called 
sarcoma in rats who had been implanted with silicone gel. FDA, 
too, was concerned about these results, and presented them to 
cancer experts within FDA and also at the National Institutes of 
Health. 
The experts noted two reassuring facts about the study. First, 
sarcomas (the type of cancer produced in the rats) occur very 
rarely in humans; the vast majority of human breast cancers are 
of a distinctly different type, called carcinomas. Secondly, 
laboratory rats are extraordinarily susceptible to sarcomas 
caused by implanting foreign objects in their bodies; the experts 
pointed out that these animals develop sarcomas after the 
implantation of a wide variety of materials, most of them 
innocuous in humans. The experts concluded (a) that the results 
of the rat study are unlikely to apply to humans; (b) that 
although a risk from silicone breast implants cannot be 
completely ruled out, there are at present no convincing animal 
or human studies that point to such a risk; and (c) that if a 
cancer risk did exist from silicone breast implants, it would be 
very small. 
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To sum it up, FDA does not believe that there is cause for alarm 
a~ present about the safety of silicone breast implan~s. But 
answers are needed to the questions outlined above in order to 
establish once and for all just what the risks are. That is why 
FDA is going to require the manufac~urers of the implants to 
supply scientific evidence of their safety. Manufacturers will 
have until the summer of 1991 to submit the data. 
Silicone breast implants coated with polyurethane foam may pose 
certain additional hazards. FDA is particularly concerned that 
the polyurethane may break down in the body, and is conducting 
laboratory research to find out whether this is the case. Based 
on the results of this research, FDA will r~-evaluate the risks 
and benefits associated with polyurethane-coated breast implants. 
What should a woman who is contemplating a silicone breast 
implan~ do? For now, the best course of action is to discuss the 
si~ua~ion frankly with her physician. (It is perfectly 
reasonable to ask the physician to see the informational material 
tha~ comes with the implant, which describes possible adverse 
effects.) She needs to talk -over the known, breast-related risks 
as well as the less well-understood, non-breast related risks 
described above, and to weigh these risks against the benefits of 
the procedure. That way she can make an informed decision about 
whether to proceed with the implant surgery. 
If a woman who already has a silicone breast implant is concerned 
about the possible risks, she too should ask her physician's 
advice. Most of the readily-observed, breast-related adverse 
effec~s discussed above are well known to physicians, as are the 
ways to treat them. As to the possibility of effects on other 
parts of the body (related to the fetus, for example, or to 
autoimmune disease, or cancer), at this point these are only 
hypothetical questions. In weighing the possible long-term risks 
of silicone breast implants, it is important to bear in mind--and 
this applies to any number of substances we encounter in everyday 
life--that not being able to completely rule out a risk does not 
necessarily mean there is one. 
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